Pegcetacoplan for 76 Weeks Maintains Proteinuria Reduction and eGFR Stabilization for Pediatric Patients: VALIANT+VALE Subgroup Analysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-OR070; Pres time: Oct 22, 2026; 05:30 PM - 05:40 PM; Location: Room 501, Convention Center; P3 | "No new safety signals were identified. Conclusion The clinical efficacy of 76 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations."
Clinical • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Pediatrics • Renal Disease
|
|
Bradley P. Dixon; Larry A. Greenbaum; María Gema Ariceta Iraola; Yael Borovitz; Antonio Mastrangelo; Nabil Melhem; Naoya Fujita; Nicole Van De Kar; Dean Wallace; Eli Khankin; Anwesha Mukherjee; Elena Surova; Johan Szamosi; Marina Vivarelli; Christoph Licht; Carla M. Nester
|